Study of INCA33890 for colon cancer after surgery and chemo
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug for people with early-stage colon cancer that has a high chance of coming back after standard treatment. It aims to see if the drug can prevent the cancer from returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove all visible colon cancer (stage II or III).
- You completed at least 3 months of chemotherapy after surgery.
- Your blood test shows signs of cancer cells remaining (called ctDNA positive).
- You have no current signs of cancer on imaging scans.
- You are well enough to carry out daily activities (ECOG 0 or 1).
- You have not had an organ or stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether giving more chemotherapy can help people who still have cancer DNA in their blood after surgery and standard chemotherapy for colorectal cancer. The goal is to prevent the cancer from coming back.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
This trial checks whether a special blood test (ctDNA methylation) can help decide the best chemotherapy after surgery for people at higher risk of colon cancer coming back. It may help spare some patients unnecessary treatment while aiming to improve outcomes for those likely to relapse.
Hear when a new CRC (Colorectal Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.